Updates in clinical trial-explored chemopreventive agents for cutaneous melanoma: mechanisms affecting melanocytes

Area of Science:

• Oncology
• Dermatology
• Pharmacology

Background:

• Cutaneous melanoma is an aggressive skin cancer with increasing incidence.
• Current primary treatment is surgical excision, but chemoprevention is gaining interest.
• Evaluating systemic chemoprevention agents is complex due to off-target effects.

Purpose of the Study:

• To review melanocyte-specific mechanisms of agents tested in clinical trials for melanoma chemoprevention.
• To focus on agents with preclinical and early clinical data for melanoma prevention.
• To identify challenges and future directions in melanoma chemoprevention.

Main Methods:

• Focused review of literature on melanoma chemoprevention agents.
• Examination of melanocyte-specific molecular and cellular mechanisms.
• Analysis of agents including NSAIDs, statins, sulforaphane, vitamin D, and N-acetylcysteine.

Main Results:

• Several agents demonstrate anti-melanoma properties via melanocyte-specific pathways.
• Nonsteroidal anti-inflammatory drugs (NSAIDs), statins, sulforaphane, vitamin D, and N-acetylcysteine show promise.
• Preclinical and early clinical data suggest potential but require further validation.

Conclusions:

• Challenges in melanoma chemoprevention include understanding precise mechanisms, optimal dosing, long-term safety, and patient selection.
• Future research should prioritize well-designed clinical trials.
• Personalized approaches integrating genetic and molecular risk factors are crucial for refining prevention strategies.